Trial Profile
A Phase 2 Trial of Amrubicin With or Without Herceptin in the Treatment of Metastatic Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Cabrellis Pharmaceuticals
- 29 Nov 2008 Trial affiliate and sponser changed from Cabrellis Pharmaceuticals to Celgene Corporation.
- 12 Sep 2007 Study withdrawn prior to recruitment.
- 18 Nov 2006 New trial record.